Fibroblast activation protein α in tumor microenvironment: Recent progression and implications (Review)
- Authors:
- Fuming Zi
- Jingsong He
- Donghua He
- Yi Li
- Li Yang
- Zhen Cai
-
Affiliations: Department of Hematology, Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China - Published online on: January 14, 2015 https://doi.org/10.3892/mmr.2015.3197
- Pages: 3203-3211
-
Copyright: © Zi et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
This article is mentioned in:
Abstract
Paget S: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8:98–101. 1989.PubMed/NCBI | |
Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet. 3:415–428. 2002.PubMed/NCBI | |
Bhowmick NA, Neilson EG and Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature. 432:332–337. 2004. View Article : Google Scholar : PubMed/NCBI | |
Hertenstein B, Hambach L, Bacigalupo A, Schmitz N, McCann S, Slavin S, Gratwohl A, Ferrant A, Elmaagacli A, Schwertfeger R, et al: Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation: Development of leukemia in donor cells after allogeneic stem cell transplantation - a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 90:969–975. 2005.PubMed/NCBI | |
Sala-Torra O, Hanna C, Loken MR, Flowers ME, Maris M, Ladne PA, Mason JR, Senitzer D, Rodriguez R, Forman SJ, et al: Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 12:511–517. 2006. View Article : Google Scholar : PubMed/NCBI | |
Xiao H, Shi J, Luo Y, Tan Y, He J, Xie W, Zhang L, Wang Y, Liu L, Wu K, et al: First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 117:5257–5260. 2011. View Article : Google Scholar : PubMed/NCBI | |
Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, Ebert BL, Al-Shahrour F, Hasserjian RP, Scadden EO, et al: Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 464:852–857. 2010. View Article : Google Scholar : PubMed/NCBI | |
Ross FM, Chiecchio L, Dagrada G, Protheroe RK, Stockley DM, Harrison CJ, Cross NC, Szubert AJ, Drayson MT and Morgan GJ: UK Myeloma Forum: The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica. 95:1221–1225. 2010. View Article : Google Scholar : PubMed/NCBI | |
Walkley CR, Olsen GH, Dworkin S, Fabb SA, Swann J, McArthur GA, Westmoreland SV, Chambon P, Scadden DT and Purton LE: A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell. 129:1097–1110. 2007. View Article : Google Scholar : PubMed/NCBI | |
Walkley CR, Shea JM, Sims NA, Purton LE and Orkin SH: Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell. 129:1081–1095. 2007. View Article : Google Scholar : PubMed/NCBI | |
Sounni NE and Noel A: Targeting the tumor microenvironment for cancer therapy. Clin Chem. 59:85–93. 2013. View Article : Google Scholar | |
Zhang J and Liu J: Tumor stroma as targets for cancer therapy. Pharmacol Ther. 137:200–215. 2013. View Article : Google Scholar : | |
Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D, Shultz L and Bhatia R: Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Blood. 121:1824–1838. 2013. View Article : Google Scholar : PubMed/NCBI | |
Konopleva MY and Jordan CT: Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 29:591–599. 2011. View Article : Google Scholar : PubMed/NCBI | |
Eck SM, Côté AL, Winkelman WD and Brinckerhoff CE: CXCR4 and matrix metalloproteinase-1 are elevated in breast carcinoma-associated fibroblasts and in normal mammary fibroblasts exposed to factors secreted by breast cancer cells. Mol Cancer Res. 7:1033–1044. 2009. View Article : Google Scholar : PubMed/NCBI | |
Gao MQ, Kim BG, Kang S, Choi YP, Park H, Kang KS and Cho NH: Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J Cell Sci. 123(Pt 20): 3507–3514. 2010. View Article : Google Scholar : PubMed/NCBI | |
Hellevik T, Pettersen I, Berg V, Winberg JO, Moe BT, Bartnes K, Paulssen RH, Busund LT, Bremnes R, Chalmers A and Martinez-Zubiaurre I: Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiat Oncol. 7:592012. View Article : Google Scholar : PubMed/NCBI | |
Berdiel-Acer M, Bohem ME, López-Doriga A, Vidal A, Salazar R, Martínez-Iniesta M, Santos C, Sanjuan X, Villanueva A and Molleví DG: Hepatic carcinoma-associated fibroblasts promote an adaptative response in colorectal cancer cells that inhibit proliferation and apoptosis: nonresistant cells die by nonapoptotic cell death. Neoplasia. 13:931–946. 2011.PubMed/NCBI | |
Mueller L, Goumas FA, Himpel S, Brilloff S, Rogiers X and Broering DC: Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases. Cancer Lett. 250:329–338. 2007. View Article : Google Scholar | |
Henriksson ML, Edin S, Dahlin AM, Oldenborg PA, Öberg Å, Van Guelpen B, Rutegård J, Stenling R and Palmqvist R: Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion. Am J Pathol. 178:1387–1394. 2011. View Article : Google Scholar : PubMed/NCBI | |
Lin ZY, Chuang YH and Chuang WL: Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells. Biomed Pharmacother. 66:525–529. 2012. View Article : Google Scholar : PubMed/NCBI | |
True LD, Zhang H, Ye M, Huang CY, Nelson PS, von Haller PD, Tjoelker LW, Kim JS, Qian WJ, Smith RD, et al: CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod Pathol. 23:1346–1356. 2010. View Article : Google Scholar : PubMed/NCBI | |
Mao Y, Keller ET, Garfield DH, Shen K and Wang J: Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 32:303–315. 2013. View Article : Google Scholar | |
Mishra PJ, Humeniuk R, Medina DJ, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW and Banerjee D: Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 68:4331–4339. 2008. View Article : Google Scholar : PubMed/NCBI | |
Lecomte J, Masset A, Blacher S, Maertens L, Gothot A, Delgaudine M, Bruyère F, Carnet O, Paupert J, Illemann M, et al: Bone marrow-derived myofibroblasts are the providers of pro-invasive matrix metalloproteinase 13 in primary tumor. Neoplasia. 14:943–951. 2012.PubMed/NCBI | |
Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, Nair S and Gilboa E: Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Clin Cancer Res. 11:5566–5571. 2005. View Article : Google Scholar : PubMed/NCBI | |
Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH, Bachovchin WW and Weiner LM: Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther. 4:351–360. 2005.PubMed/NCBI | |
Loeffler M, Kruger JA, Niethammer AG and Reisfeld RA: Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest. 116:1955–1962. 2006. View Article : Google Scholar : PubMed/NCBI | |
Santos AM, Jung J, Aziz N, Kissil JL and Puré E: Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 119:3613–3625. 2009. View Article : Google Scholar : PubMed/NCBI | |
Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA and Fearon DT: Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 330:827–830. 2010. View Article : Google Scholar : PubMed/NCBI | |
Rettig WJ, Chesa PG, Beresford HR, Feickert HJ, Jennings MT, Cohen J, Oettgen HF and Old LJ: Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets. Cancer Res. 46(12 Pt 2): 6406–6412. 1986.PubMed/NCBI | |
Rettig WJ, Garin-Chesa P, Beresford HR, Oettgen HF, Melamed MR and Old LJ: Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci USA. 85:3110–3114. 1988. View Article : Google Scholar : PubMed/NCBI | |
Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Ozer HL, Schwab M, Albino AP and Old LJ: Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. 53:3327–3335. 1993.PubMed/NCBI | |
Rettig WJ, Su SL, Fortunato SR, Scanlan MJ, Raj BK, Garin-Chesa P, Healey JH and Old LJ: Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int J Cancer. 58:385–392. 1994. View Article : Google Scholar : PubMed/NCBI | |
Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, Old LJ and Rettig WJ: Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA. 91:5657–5661. 1994. View Article : Google Scholar : PubMed/NCBI | |
Welt S, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, Carswell EA, Cohen A, Larson SM, Old LJ, et al: Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol. 12:1193–1203. 1994.PubMed/NCBI | |
Niedermeyer J, Scanlan MJ, Garin-Chesa P, Daiber C, Fiebig HH, Old LJ, Rettig WJ and Schnapp A: Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int J Cancer. 71:383–389. 1997. View Article : Google Scholar : PubMed/NCBI | |
Aoyama A and Chen WT: A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells. Proc Natl Acad Sci USA. 87:8296–8300. 1990. View Article : Google Scholar : PubMed/NCBI | |
Monsky WL, Lin CY, Aoyama A, Kelly T, Akiyama SK, Mueller SC and Chen WT: A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res. 54:5702–5710. 1994.PubMed/NCBI | |
Piñeiro-Sánchez ML, Goldstein LA, Dodt J, Howard L, Yeh Y, Tran H, Argraves WS and Chen WT: Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem. 272:7595–7601. 1997. View Article : Google Scholar : PubMed/NCBI | |
Mathew S, Scanlan MJ, Mohan Raj BK, Murty VV, Garin-Chesa P, Old LJ, Rettig WJ and Chaganti RS: The gene for fibroblast activation protein alpha (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. Genomics. 25:335–337. 1995. View Article : Google Scholar : PubMed/NCBI | |
Kelly T: Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat. 8:51–58. 2005. View Article : Google Scholar : PubMed/NCBI | |
Aertgeerts K, Levin I, Shi L, Snell GP, Jennings A, Prasad GS, Zhang Y, Kraus ML, Salakian S, Sridhar V, et al: Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem. 280:19441–19444. 2005. View Article : Google Scholar : PubMed/NCBI | |
Rosenblum JS and Kozarich JW: Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol. 7:496–504. 2003. View Article : Google Scholar : PubMed/NCBI | |
Yazbeck R, Howarth GS and Abbott CA: Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci. 30:600–607. 2009. View Article : Google Scholar : PubMed/NCBI | |
Sedo A and Malík R: Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim Biophys Acta. 1550:107–116. 2001. View Article : Google Scholar | |
Qi SY, Riviere PJ, Trojnar J, Junien JL and Akinsanya KO: Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem J. 373(Pt 1): 179–189. 2003. View Article : Google Scholar : PubMed/NCBI | |
Ghersi G, Zhao Q, Salamone M, Yeh Y, Zucker S and Chen WT: The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res. 66:4652–4661. 2006. View Article : Google Scholar : PubMed/NCBI | |
Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ and Rettig WJ: Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 274:36505–36512. 1999. View Article : Google Scholar : PubMed/NCBI | |
Abbott CA, Baker E, Sutherland GR and McCaughan GW: Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics. 40:331–338. 1994. View Article : Google Scholar : PubMed/NCBI | |
Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW and Gorrell MD: Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem. 267:6140–6150. 2000. View Article : Google Scholar : PubMed/NCBI | |
Yokotani N, Doi K, Wenthold RJ and Wada K: Non-conservation of a catalytic residue in a dipeptidyl aminopeptidase IV-related protein encoded by a gene on human chromosome 7. Hum Mol Genet. 2:1037–1039. 1993. View Article : Google Scholar : PubMed/NCBI | |
Zhang J, Valianou M and Cheng JD: Identification and characterization of the promoter of fibroblast activation protein. Front Biosci (Elite Ed). 2:1154–1163. 2010. View Article : Google Scholar : | |
Garin-Chesa P, Old LJ and Rettig WJ: Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 87:7235–7239. 1990. View Article : Google Scholar : PubMed/NCBI | |
Kelly T, Kechelava S, Rozypal TL, West KW and Korourian S: Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers. Mod Pathol. 11:855–863. 1998.PubMed/NCBI | |
Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Müller E, Rettig WJ and Gorrell MD: Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology. 29:1768–1778. 1999. View Article : Google Scholar : PubMed/NCBI | |
Acharya PS, Zukas A, Chandan V, Katzenstein AL and Puré E: Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol. 37:352–360. 2006. View Article : Google Scholar : PubMed/NCBI | |
Bauer S, Jendro MC, Wadle A, Kleber S, Stenner F, Dinser R, Reich A, Faccin E, Gödde S, Dinges H, et al: Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther. 8:R1712006. View Article : Google Scholar : PubMed/NCBI | |
Rovedatti L, Di Sabatino A, Knowles CH, Sengupta N, Biancheri P, Corazza GR and MacDonald TT: Fibroblast activation protein expression in Crohn’s disease strictures. Inflamm Bowel Dis. 17:1251–1253. 2011. View Article : Google Scholar | |
Brokopp CE, Schoenauer R, Richards P, Bauer S, Lohmann C, Emmert MY, Weber B, Winnik S, Aikawa E, Graves K, et al: Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. Eur Heart J. 32:2713–2722. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J Jr and Yaccoby S: Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br J Haematol. 133:83–92. 2006. View Article : Google Scholar : PubMed/NCBI | |
Bae S, Park CW, Son HK, Ju HK, Paik D, Jeon CJ, Koh GY, Kim J and Kim H: Fibroblast activation protein alpha identifies mesenchymal stromal cells from human bone marrow. Br J Haematol. 142:827–830. 2008. View Article : Google Scholar : PubMed/NCBI | |
Haniffa MA, Collin MP, Buckley CD and Dazzi F: Mesenchymal stem cells: the fibroblasts’ new clothes? Haematologica. 94:258–263. 2009. View Article : Google Scholar : | |
Shi M, Yu DH, Chen Y, Zhao CY, Zhang J, Liu QH, Ni CR and Zhu MH: Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol. 18:840–846. 2012. View Article : Google Scholar : PubMed/NCBI | |
Iwasa S, Okada K, Chen WT, Jin X, Yamane T, Ooi A and Mitsumata M: Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. Cancer Lett. 227:229–236. 2005. View Article : Google Scholar : PubMed/NCBI | |
Mori Y, Kono K, Matsumoto Y, Fujii H, Yamane T, Mitsumata M and Chen WT: The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma. Oncology. 67:411–419. 2004. View Article : Google Scholar | |
Jin X, Iwasa S, Okada K, Mitsumata M and Ooi A: Expression patterns of seprase, a membrane serine protease, in cervical carcinoma and cervical intraepithelial neoplasm. Anticancer Res. 23:3195–3198. 2003.PubMed/NCBI | |
Mentlein R, Hattermann K, Hemion C, Jungbluth AA and Held-Feindt J: Expression and role of the cell surface protease seprase/fibroblast activation protein-α (FAP-α) in astroglial tumors. Biol Chem. 392:199–207. 2011. View Article : Google Scholar | |
Wäster P, Rosdahl I, Gilmore BF and Seifert O: Ultraviolet exposure of melanoma cells induces fibroblast activation protein-α in fibroblasts: Implications for melanoma invasion. Int J Oncol. 39:193–202. 2011. | |
Cheng JD, Dunbrack RL Jr, Valianou M, Rogatko A, Alpaugh RK and Weiner LM: Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 62:4767–4772. 2002.PubMed/NCBI | |
Huang Y, Wang S and Kelly T: Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res. 64:2712–2716. 2004. View Article : Google Scholar : PubMed/NCBI | |
Goodman JD, Rozypal TL and Kelly T: Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clin Exp Metastasis. 20:459–470. 2003. View Article : Google Scholar : PubMed/NCBI | |
Lai D, Ma L and Wang F: Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells. Int J Oncol. 41:541–550. 2012.PubMed/NCBI | |
Fischer E, Chaitanya K, Wüest T, Wadle A, Scott AM, van den Broek M, Schibli R, Bauer S and Renner C: Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clin Cancer Res. 18:6208–6218. 2012. View Article : Google Scholar : PubMed/NCBI | |
Pennisi A, Li X, Ling W, Khan S, Gaddy D, Suva LJ, Barlogie B, Shaughnessy JD, Aziz N and Yaccoby S: Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. Br J Haematol. 145:775–787. 2009. View Article : Google Scholar : PubMed/NCBI | |
Adams S, Miller GT, Jesson MI, Watanabe T, Jones B and Wallner BP: PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 64:5471–5480. 2004. View Article : Google Scholar : PubMed/NCBI | |
van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1643–1647. 1991. View Article : Google Scholar : PubMed/NCBI | |
Liao D, Luo Y, Markowitz D, Xiang R and Reisfeld RA: Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One. 4:e79652009. View Article : Google Scholar : PubMed/NCBI | |
Huber MA, Kraut N, Park JE, Schubert RD, Rettig WJ, Peter RU and Garin-Chesa P: Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermatol. 120:182–188. 2003. View Article : Google Scholar : PubMed/NCBI | |
Tsujimoto H, Nishizuka S, Redpath JL and Stanbridge EJ: Differential gene expression in tumorigenic and nontumorigenic HeLa × normal human fibroblast hybrid cells. Mol Carcinog. 26:298–304. 1999. View Article : Google Scholar : PubMed/NCBI | |
Brown DD, Wang Z, Furlow JD, Kanamori A, Schwartzman RA, Remo BF and Pinder A: The thyroid hormone-induced tail resorption program during Xenopus laevis metamorphosis. Proc Natl Acad Sci USA. 93:1924–1929. 1996. View Article : Google Scholar : PubMed/NCBI | |
Ramirez-Montagut T, Blachere NE, Sviderskaya EV, Bennett DC, Rettig WJ, Garin-Chesa P and Houghton AN: FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene. 23:5435–5446. 2004. View Article : Google Scholar : PubMed/NCBI | |
Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, Espeli M, Kraman M, McKenna B, Wells RJ, et al: Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med. 210:1137–1151. 2013. View Article : Google Scholar : PubMed/NCBI | |
Niedermeyer J, Kriz M, Hilberg F, Garin-Chesa P, Bamberger U, Lenter MC, Park J, Viertel B, Püschner H, Mauz M, Rettig WJ and Schnapp A: Targeted disruption of mouse fibroblast activation protein. Mol Cell Biol. 20:1089–1094. 2000. View Article : Google Scholar : PubMed/NCBI | |
Jacob M, Chang L and Puré E: Fibroblast activation protein in remodeling tissues. Curr Mol Med. 12:1220–1243. 2012. View Article : Google Scholar : PubMed/NCBI | |
Ghersi G, Dong H, Goldstein LA, Yeh Y, Hakkinen L, Larjava HS and Chen WT: Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem. 277:29231–29241. 2002. View Article : Google Scholar : PubMed/NCBI | |
Chen WT and Kelly T: Seprase complexes in cellular invasiveness. Cancer Metastasis Rev. 22:259–269. 2003. View Article : Google Scholar : PubMed/NCBI | |
O’Brien P and O’Connor BF: Seprase: an overview of an important matrix serine protease. Biochim Biophys Acta. 1784:1130–1145. 2008. View Article : Google Scholar | |
Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E and Cheng JD: FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer. 11:2452011. View Article : Google Scholar : PubMed/NCBI | |
Wang XM, Yu DM, McCaughan GW and Gorrell MD: Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology. 42:935–945. 2005. View Article : Google Scholar : PubMed/NCBI | |
Wikberg ML, Edin S, Lundberg IV, Van Guelpen B, Dahlin AM, Rutegård J, Stenling R, Oberg A and Palmqvist R: High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol. 34:1013–1020. 2013. View Article : Google Scholar : PubMed/NCBI | |
Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, Hoffman JP, Weiner LM and Cheng JD: Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 37:154–158. 2008. View Article : Google Scholar : PubMed/NCBI | |
Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT and Cheng JD: Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 13:1736–1741. 2007. View Article : Google Scholar : PubMed/NCBI | |
Saigusa S, Toiyama Y, Tanaka K, Yokoe T, Okugawa Y, Fujikawa H, Matsusita K, Kawamura M, Inoue Y, Miki C and Kusunoki M: Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy. Int J Oncol. 38:655–663. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ariga N, Sato E, Ohuchi N, Nagura H and Ohtani H: Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer. 95:67–72. 2001. View Article : Google Scholar : PubMed/NCBI | |
Lee KN, Jackson KW, Christiansen VJ, Chung KH and McKee PA: A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood. 103:3783–3788. 2004. View Article : Google Scholar : PubMed/NCBI | |
Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG and McKee PA: Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood. 107:1397–1404. 2006. View Article : Google Scholar | |
Keane FM, Nadvi NA, Yao TW and Gorrell MD: Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α. FEBS J. 278:1316–1332. 2011. View Article : Google Scholar : PubMed/NCBI | |
Huang CH, Suen CS, Lin CT, Chien CH, Lee HY, Chung KM, Tsai TY, Jiaang WT, Hwang MJ and Chen X: Cleavage-site specificity of prolyl endopeptidase FAP investigated with a full-length protein substrate. J Biochem. 149:685–692. 2011. View Article : Google Scholar : PubMed/NCBI | |
Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, et al: A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 9:1639–1647. 2003.PubMed/NCBI | |
Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jäger D, Renner C, Tanswell P, Kunz U, Amelsberg A, Kuthan H and Stehle G: Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 26:44–48. 2003. View Article : Google Scholar : PubMed/NCBI | |
Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP and Rosenberg SA: Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 210:1125–1135. 2013. View Article : Google Scholar : PubMed/NCBI | |
Petrausch U, Schuberth PC, Hagedorn C, Soltermann A, Tomaszek S, Stahel R, Weder W and Renner C: Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer. 12:6152012. View Article : Google Scholar : PubMed/NCBI |